Sarah Milgrom
Concepts (370)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 42 | 2026 | 173 | 11.990 |
Why?
| | Radiotherapy, Intensity-Modulated | 17 | 2026 | 143 | 4.060 |
Why?
| | Positron Emission Tomography Computed Tomography | 17 | 2026 | 122 | 3.750 |
Why?
| | Radiotherapy | 15 | 2026 | 209 | 2.380 |
Why?
| | Fluorodeoxyglucose F18 | 8 | 2026 | 164 | 2.290 |
Why?
| | Tumor Burden | 7 | 2026 | 326 | 2.280 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 16 | 2026 | 150 | 2.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 35 | 2026 | 1998 | 2.240 |
Why?
| | Lymphoma | 10 | 2025 | 251 | 2.030 |
Why?
| | Whole-Body Irradiation | 3 | 2026 | 73 | 1.880 |
Why?
| | Radiation Injuries | 9 | 2025 | 149 | 1.870 |
Why?
| | Radiotherapy Dosage | 18 | 2026 | 289 | 1.680 |
Why?
| | Central Nervous System Neoplasms | 9 | 2021 | 177 | 1.670 |
Why?
| | Radiopharmaceuticals | 6 | 2023 | 210 | 1.570 |
Why?
| | Hematologic Neoplasms | 2 | 2026 | 170 | 1.520 |
Why?
| | Neoplasm Staging | 32 | 2026 | 1488 | 1.430 |
Why?
| | Lymphoma, Non-Hodgkin | 6 | 2024 | 124 | 1.430 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 8 | 2024 | 195 | 1.250 |
Why?
| | Neoplasms | 9 | 2026 | 2954 | 1.200 |
Why?
| | Sarcoma | 2 | 2023 | 209 | 1.170 |
Why?
| | Salvage Therapy | 11 | 2024 | 166 | 1.150 |
Why?
| | Neoplasm Recurrence, Local | 13 | 2023 | 1160 | 1.150 |
Why?
| | Mediastinal Neoplasms | 5 | 2021 | 54 | 1.070 |
Why?
| | Endometrial Neoplasms | 4 | 2014 | 205 | 1.070 |
Why?
| | Prognosis | 24 | 2026 | 4351 | 1.040 |
Why?
| | Combined Modality Therapy | 22 | 2024 | 1271 | 1.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 7 | 2024 | 704 | 1.010 |
Why?
| | Radiotherapy, Adjuvant | 7 | 2024 | 222 | 0.960 |
Why?
| | Humans | 126 | 2026 | 146342 | 0.960 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2026 | 11 | 0.930 |
Why?
| | Proton Therapy | 3 | 2026 | 16 | 0.920 |
Why?
| | Positron-Emission Tomography | 9 | 2025 | 343 | 0.920 |
Why?
| | Neoplasms, Radiation-Induced | 2 | 2026 | 100 | 0.920 |
Why?
| | Rhabdomyosarcoma | 2 | 2024 | 65 | 0.910 |
Why?
| | Neoplasms, Second Primary | 2 | 2026 | 103 | 0.890 |
Why?
| | Sarcoma, Ewing | 2 | 2024 | 103 | 0.880 |
Why?
| | Doxorubicin | 15 | 2026 | 416 | 0.850 |
Why?
| | Child | 31 | 2026 | 22693 | 0.830 |
Why?
| | Disease Progression | 7 | 2024 | 2867 | 0.830 |
Why?
| | Young Adult | 37 | 2026 | 14330 | 0.790 |
Why?
| | Radiation | 2 | 2020 | 24 | 0.790 |
Why?
| | Clinical Trials as Topic | 2 | 2026 | 1064 | 0.790 |
Why?
| | Craniopharyngioma | 1 | 2024 | 77 | 0.780 |
Why?
| | Radiation Exposure | 1 | 2023 | 62 | 0.750 |
Why?
| | Pituitary Neoplasms | 1 | 2024 | 190 | 0.730 |
Why?
| | Adolescent | 35 | 2026 | 22557 | 0.720 |
Why?
| | Adenocarcinoma | 3 | 2014 | 927 | 0.720 |
Why?
| | Lymphoma, Follicular | 5 | 2020 | 57 | 0.720 |
Why?
| | Salivary Glands | 2 | 2021 | 36 | 0.710 |
Why?
| | Smiling | 1 | 2021 | 6 | 0.700 |
Why?
| | Xerostomia | 1 | 2021 | 13 | 0.680 |
Why?
| | Retrospective Studies | 39 | 2026 | 17438 | 0.670 |
Why?
| | Bleomycin | 10 | 2026 | 255 | 0.670 |
Why?
| | Tooth Abnormalities | 1 | 2021 | 17 | 0.670 |
Why?
| | Brachytherapy | 1 | 2021 | 132 | 0.640 |
Why?
| | Chemoradiotherapy | 9 | 2021 | 238 | 0.620 |
Why?
| | Face | 1 | 2021 | 177 | 0.620 |
Why?
| | Cancer Survivors | 2 | 2026 | 348 | 0.610 |
Why?
| | Aged, 80 and over | 23 | 2026 | 8391 | 0.600 |
Why?
| | Vinblastine | 9 | 2025 | 75 | 0.600 |
Why?
| | Intraocular Lymphoma | 2 | 2016 | 3 | 0.590 |
Why?
| | Dacarbazine | 9 | 2025 | 98 | 0.590 |
Why?
| | Aged | 43 | 2026 | 26432 | 0.580 |
Why?
| | Adult | 54 | 2026 | 41087 | 0.580 |
Why?
| | Infertility, Female | 2 | 2025 | 124 | 0.570 |
Why?
| | Middle Aged | 51 | 2026 | 36619 | 0.560 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 4 | 2019 | 21 | 0.560 |
Why?
| | Organs at Risk | 4 | 2026 | 37 | 0.560 |
Why?
| | Rectal Neoplasms | 3 | 2016 | 160 | 0.550 |
Why?
| | Female | 65 | 2026 | 79499 | 0.550 |
Why?
| | Cerebellar Neoplasms | 1 | 2020 | 169 | 0.530 |
Why?
| | Radiotherapy, Image-Guided | 4 | 2026 | 40 | 0.530 |
Why?
| | Medulloblastoma | 1 | 2020 | 208 | 0.520 |
Why?
| | Breast Neoplasms | 6 | 2026 | 2418 | 0.520 |
Why?
| | Recurrence | 9 | 2020 | 1133 | 0.500 |
Why?
| | Male | 57 | 2026 | 73396 | 0.500 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 95 | 0.490 |
Why?
| | Leukemia, Biphenotypic, Acute | 1 | 2016 | 4 | 0.490 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2023 | 702 | 0.480 |
Why?
| | Treatment Outcome | 27 | 2026 | 11821 | 0.470 |
Why?
| | Patient Satisfaction | 1 | 2020 | 706 | 0.470 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 563 | 0.460 |
Why?
| | Mediastinum | 4 | 2026 | 23 | 0.440 |
Why?
| | Graft vs Host Disease | 2 | 2024 | 283 | 0.440 |
Why?
| | Radiation Oncology | 2 | 2026 | 83 | 0.430 |
Why?
| | Eye Diseases | 1 | 2016 | 100 | 0.430 |
Why?
| | Brain Neoplasms | 3 | 2023 | 1325 | 0.430 |
Why?
| | Lower Urinary Tract Symptoms | 2 | 2026 | 62 | 0.430 |
Why?
| | Follow-Up Studies | 16 | 2025 | 5439 | 0.420 |
Why?
| | Survival Rate | 12 | 2021 | 2092 | 0.410 |
Why?
| | Vincristine | 6 | 2026 | 148 | 0.400 |
Why?
| | Disease-Free Survival | 12 | 2020 | 778 | 0.400 |
Why?
| | Glycolysis | 3 | 2023 | 342 | 0.390 |
Why?
| | Endometrium | 1 | 2013 | 64 | 0.390 |
Why?
| | Peritoneal Cavity | 1 | 2013 | 30 | 0.390 |
Why?
| | Palate, Hard | 1 | 2012 | 5 | 0.380 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 115 | 0.380 |
Why?
| | Cyclophosphamide | 5 | 2026 | 275 | 0.370 |
Why?
| | Stomach Neoplasms | 3 | 2019 | 128 | 0.370 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2019 | 44 | 0.370 |
Why?
| | Lymphoma, B-Cell | 3 | 2021 | 150 | 0.370 |
Why?
| | Child, Preschool | 10 | 2026 | 11913 | 0.370 |
Why?
| | Mastectomy, Simple | 1 | 2012 | 1 | 0.360 |
Why?
| | Image Enhancement | 1 | 2013 | 198 | 0.360 |
Why?
| | Neoadjuvant Therapy | 2 | 2016 | 475 | 0.350 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2012 | 118 | 0.340 |
Why?
| | Carcinoma, Lobular | 1 | 2012 | 59 | 0.340 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2012 | 92 | 0.340 |
Why?
| | Prednisone | 4 | 2026 | 229 | 0.330 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2012 | 99 | 0.330 |
Why?
| | Radiotherapy, Conformal | 2 | 2026 | 75 | 0.320 |
Why?
| | Rituximab | 4 | 2026 | 208 | 0.310 |
Why?
| | Biopsy | 6 | 2020 | 1075 | 0.310 |
Why?
| | Disease Management | 6 | 2019 | 651 | 0.300 |
Why?
| | Cellulitis | 1 | 2009 | 55 | 0.290 |
Why?
| | Tomography, X-Ray Computed | 7 | 2023 | 2786 | 0.290 |
Why?
| | Antineoplastic Agents | 6 | 2025 | 2219 | 0.290 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2014 | 628 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 7 | 2020 | 970 | 0.280 |
Why?
| | United States | 6 | 2026 | 16136 | 0.280 |
Why?
| | Lymphocytes | 3 | 2020 | 379 | 0.280 |
Why?
| | Lymphoma, Mantle-Cell | 2 | 2019 | 36 | 0.270 |
Why?
| | Organ Sparing Treatments | 2 | 2026 | 37 | 0.260 |
Why?
| | Coronary Artery Disease | 2 | 2026 | 751 | 0.250 |
Why?
| | Consensus | 3 | 2024 | 467 | 0.250 |
Why?
| | Survival Analysis | 6 | 2020 | 1378 | 0.240 |
Why?
| | Cardiotoxicity | 2 | 2023 | 35 | 0.240 |
Why?
| | Lung Neoplasms | 3 | 2026 | 2675 | 0.240 |
Why?
| | Pregnancy Complications, Neoplastic | 2 | 2017 | 64 | 0.240 |
Why?
| | Ifosfamide | 1 | 2026 | 39 | 0.240 |
Why?
| | Testicular Neoplasms | 2 | 2018 | 108 | 0.230 |
Why?
| | Credentialing | 1 | 2026 | 21 | 0.230 |
Why?
| | Radiation Pneumonitis | 2 | 2016 | 31 | 0.230 |
Why?
| | Multiple Myeloma | 2 | 2020 | 310 | 0.230 |
Why?
| | Patient Selection | 2 | 2022 | 728 | 0.230 |
Why?
| | Pelvic Neoplasms | 1 | 2025 | 24 | 0.230 |
Why?
| | Heart | 3 | 2018 | 626 | 0.220 |
Why?
| | Urinary Tract | 1 | 2025 | 47 | 0.220 |
Why?
| | Urodynamics | 1 | 2025 | 44 | 0.220 |
Why?
| | Lymph Node Excision | 2 | 2019 | 174 | 0.220 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2017 | 108 | 0.210 |
Why?
| | Risk Factors | 6 | 2026 | 10921 | 0.210 |
Why?
| | Risk Assessment | 6 | 2023 | 3712 | 0.210 |
Why?
| | Leukemia | 2 | 2017 | 246 | 0.210 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 23 | 0.210 |
Why?
| | Central Nervous System | 3 | 2021 | 278 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 4 | 2019 | 3926 | 0.200 |
Why?
| | Uterus | 1 | 2025 | 227 | 0.200 |
Why?
| | Quality Assurance, Health Care | 1 | 2025 | 349 | 0.200 |
Why?
| | Lymphadenopathy | 1 | 2023 | 8 | 0.190 |
Why?
| | Lymphatic Metastasis | 3 | 2014 | 335 | 0.190 |
Why?
| | Virtual Reality | 1 | 2025 | 83 | 0.190 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2024 | 103 | 0.190 |
Why?
| | Comprehension | 1 | 2025 | 175 | 0.190 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 193 | 0.190 |
Why?
| | Neoplasm Grading | 4 | 2019 | 313 | 0.190 |
Why?
| | Remission Induction | 3 | 2018 | 308 | 0.180 |
Why?
| | Protons | 2 | 2020 | 96 | 0.180 |
Why?
| | Brain Stem Neoplasms | 1 | 2023 | 86 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2024 | 272 | 0.170 |
Why?
| | Radiometry | 2 | 2019 | 56 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2021 | 16 | 0.170 |
Why?
| | Gastric Mucosa | 2 | 2019 | 54 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2013 | 429 | 0.170 |
Why?
| | Cohort Studies | 6 | 2024 | 6077 | 0.170 |
Why?
| | Transplantation, Autologous | 3 | 2018 | 306 | 0.170 |
Why?
| | Societies, Medical | 1 | 2026 | 907 | 0.170 |
Why?
| | Survivors | 2 | 2023 | 526 | 0.170 |
Why?
| | Multimodal Imaging | 3 | 2017 | 137 | 0.170 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2021 | 88 | 0.170 |
Why?
| | Radium | 1 | 2020 | 4 | 0.170 |
Why?
| | Imaging, Three-Dimensional | 1 | 2025 | 582 | 0.160 |
Why?
| | Breath Holding | 2 | 2017 | 10 | 0.160 |
Why?
| | Postoperative Complications | 1 | 2014 | 3034 | 0.160 |
Why?
| | Long Term Adverse Effects | 1 | 2020 | 13 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2025 | 389 | 0.160 |
Why?
| | Cranial Irradiation | 2 | 2023 | 85 | 0.160 |
Why?
| | Etoposide | 4 | 2026 | 169 | 0.160 |
Why?
| | Patient Education as Topic | 1 | 2025 | 770 | 0.150 |
Why?
| | Skin Neoplasms | 2 | 2018 | 806 | 0.150 |
Why?
| | Stem Cell Transplantation | 2 | 2018 | 190 | 0.150 |
Why?
| | Plasmacytoma | 1 | 2019 | 19 | 0.150 |
Why?
| | Cardiology | 1 | 2022 | 363 | 0.140 |
Why?
| | CD4-CD8 Ratio | 1 | 2018 | 23 | 0.140 |
Why?
| | Postoperative Care | 2 | 2019 | 301 | 0.140 |
Why?
| | Radiation Dosage | 1 | 2020 | 193 | 0.140 |
Why?
| | Mycosis Fungoides | 1 | 2018 | 63 | 0.140 |
Why?
| | Prospective Studies | 6 | 2026 | 8123 | 0.140 |
Why?
| | Methotrexate | 2 | 2017 | 234 | 0.140 |
Why?
| | Electrons | 1 | 2018 | 82 | 0.140 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 29 | 0.140 |
Why?
| | Glioma | 1 | 2023 | 425 | 0.140 |
Why?
| | Area Under Curve | 1 | 2019 | 335 | 0.130 |
Why?
| | Peritoneal Neoplasms | 1 | 2019 | 103 | 0.130 |
Why?
| | Radiotherapy Setup Errors | 1 | 2017 | 3 | 0.130 |
Why?
| | Platelet Count | 1 | 2017 | 95 | 0.130 |
Why?
| | Autografts | 1 | 2018 | 56 | 0.130 |
Why?
| | Hypothyroidism | 1 | 2018 | 68 | 0.130 |
Why?
| | Craniospinal Irradiation | 1 | 2017 | 5 | 0.130 |
Why?
| | Biomarkers | 5 | 2026 | 4340 | 0.130 |
Why?
| | Dendritic Cell Sarcoma, Follicular | 1 | 2017 | 4 | 0.130 |
Why?
| | Leukocyte Count | 1 | 2017 | 321 | 0.130 |
Why?
| | Eye Neoplasms | 1 | 2017 | 31 | 0.130 |
Why?
| | Osteogenesis Imperfecta | 2 | 2007 | 14 | 0.120 |
Why?
| | Uncertainty | 1 | 2017 | 145 | 0.120 |
Why?
| | Spinal Cord Diseases | 1 | 2017 | 42 | 0.120 |
Why?
| | Pentostatin | 1 | 2016 | 4 | 0.120 |
Why?
| | Neoplasm, Residual | 1 | 2017 | 143 | 0.120 |
Why?
| | Axilla | 2 | 2017 | 51 | 0.120 |
Why?
| | Photopheresis | 1 | 2016 | 9 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2022 | 2113 | 0.120 |
Why?
| | Methylprednisolone | 1 | 2016 | 58 | 0.120 |
Why?
| | Plasmablastic Lymphoma | 1 | 2015 | 8 | 0.120 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 121 | 0.120 |
Why?
| | Confidence Intervals | 1 | 2016 | 329 | 0.120 |
Why?
| | Collagen Type I | 2 | 2007 | 144 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2016 | 302 | 0.110 |
Why?
| | Caregivers | 2 | 2025 | 1080 | 0.110 |
Why?
| | Abortion, Spontaneous | 1 | 2016 | 120 | 0.110 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2016 | 141 | 0.110 |
Why?
| | Congenital Abnormalities | 1 | 2016 | 108 | 0.110 |
Why?
| | Hysterectomy | 2 | 2013 | 139 | 0.110 |
Why?
| | Anxiety | 1 | 2023 | 1125 | 0.110 |
Why?
| | Tacrolimus | 1 | 2016 | 192 | 0.110 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 416 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 893 | 0.110 |
Why?
| | Proportional Hazards Models | 4 | 2020 | 1331 | 0.110 |
Why?
| | Blood Platelets | 1 | 2017 | 382 | 0.100 |
Why?
| | Receptors, Progesterone | 2 | 2014 | 242 | 0.100 |
Why?
| | Risk | 1 | 2016 | 920 | 0.100 |
Why?
| | Age Factors | 1 | 2021 | 3347 | 0.100 |
Why?
| | Kidney Neoplasms | 1 | 2018 | 419 | 0.100 |
Why?
| | Receptors, Estrogen | 2 | 2014 | 406 | 0.090 |
Why?
| | Carboplatin | 1 | 2013 | 168 | 0.090 |
Why?
| | Spinal Cord | 1 | 2015 | 378 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 474 | 0.090 |
Why?
| | Fluorouracil | 1 | 2013 | 231 | 0.090 |
Why?
| | Lung | 2 | 2016 | 4122 | 0.090 |
Why?
| | Pelvis | 1 | 2013 | 129 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1195 | 0.090 |
Why?
| | Paclitaxel | 1 | 2013 | 260 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 197 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1712 | 0.090 |
Why?
| | Neutrophils | 1 | 2017 | 1133 | 0.090 |
Why?
| | Immunosuppressive Agents | 1 | 2016 | 829 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2020 | 1408 | 0.090 |
Why?
| | Cisplatin | 1 | 2013 | 347 | 0.080 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2014 | 220 | 0.080 |
Why?
| | Brain | 2 | 2020 | 2991 | 0.080 |
Why?
| | Models, Biological | 1 | 2018 | 1761 | 0.080 |
Why?
| | Immunotherapy | 1 | 2015 | 671 | 0.080 |
Why?
| | Contrast Media | 1 | 2013 | 493 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2240 | 0.070 |
Why?
| | Patient Compliance | 1 | 2013 | 589 | 0.070 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2020 | 141 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2014 | 776 | 0.070 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2019 | 96 | 0.070 |
Why?
| | Cytarabine | 2 | 2018 | 66 | 0.060 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1339 | 0.060 |
Why?
| | Integrins | 1 | 2007 | 88 | 0.060 |
Why?
| | Nerve Growth Factor | 1 | 2026 | 36 | 0.060 |
Why?
| | Proteoglycans | 1 | 2007 | 111 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2014 | 1591 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2014 | 874 | 0.060 |
Why?
| | Time Factors | 4 | 2018 | 7109 | 0.060 |
Why?
| | Treatment Failure | 2 | 2018 | 361 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 297 | 0.060 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2026 | 155 | 0.060 |
Why?
| | Glycine | 1 | 2006 | 184 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2017 | 504 | 0.050 |
Why?
| | Fertility Preservation | 1 | 2025 | 57 | 0.050 |
Why?
| | Clinical Decision-Making | 2 | 2019 | 365 | 0.050 |
Why?
| | Creatinine | 1 | 2026 | 511 | 0.050 |
Why?
| | American Heart Association | 1 | 2026 | 364 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 14 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 55 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2026 | 494 | 0.050 |
Why?
| | Standard of Care | 1 | 2024 | 81 | 0.050 |
Why?
| | X-Rays | 1 | 2023 | 27 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2024 | 82 | 0.050 |
Why?
| | Regression Analysis | 2 | 2016 | 999 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2023 | 38 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2016 | 1298 | 0.050 |
Why?
| | Pregnancy | 3 | 2025 | 7230 | 0.050 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2022 | 12 | 0.050 |
Why?
| | Cytidine Deaminase | 1 | 2023 | 59 | 0.050 |
Why?
| | Phenotype | 3 | 2021 | 3206 | 0.050 |
Why?
| | Terminology as Topic | 1 | 2024 | 253 | 0.050 |
Why?
| | Brain Stem | 1 | 2023 | 101 | 0.040 |
Why?
| | Ribose | 1 | 2021 | 21 | 0.040 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 75 | 0.040 |
Why?
| | Troponin T | 1 | 2021 | 63 | 0.040 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 55 | 0.040 |
Why?
| | Feedback | 1 | 2021 | 183 | 0.040 |
Why?
| | Radiosurgery | 1 | 2024 | 398 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 356 | 0.040 |
Why?
| | Automation | 1 | 2020 | 104 | 0.040 |
Why?
| | Risk Management | 1 | 2020 | 81 | 0.040 |
Why?
| | Prevalence | 2 | 2016 | 2861 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2936 | 0.040 |
Why?
| | Mesentery | 1 | 2019 | 44 | 0.040 |
Why?
| | Infant | 2 | 2025 | 10114 | 0.040 |
Why?
| | Workflow | 1 | 2020 | 182 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 1149 | 0.030 |
Why?
| | Busulfan | 1 | 2018 | 15 | 0.030 |
Why?
| | Respiration | 1 | 2019 | 208 | 0.030 |
Why?
| | Safety | 1 | 2020 | 347 | 0.030 |
Why?
| | Melphalan | 1 | 2018 | 43 | 0.030 |
Why?
| | Carmustine | 1 | 2018 | 52 | 0.030 |
Why?
| | Algorithms | 1 | 2025 | 1849 | 0.030 |
Why?
| | Inhalation | 1 | 2017 | 28 | 0.030 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2017 | 32 | 0.030 |
Why?
| | Breast | 1 | 2018 | 155 | 0.030 |
Why?
| | Subacute Combined Degeneration | 1 | 2017 | 1 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1724 | 0.030 |
Why?
| | Photons | 1 | 2017 | 67 | 0.030 |
Why?
| | Injections, Spinal | 1 | 2017 | 120 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2018 | 219 | 0.030 |
Why?
| | New York | 1 | 2016 | 128 | 0.030 |
Why?
| | Orbit | 1 | 2017 | 67 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2019 | 257 | 0.030 |
Why?
| | Homocysteine | 1 | 2017 | 152 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2019 | 511 | 0.030 |
Why?
| | Procarbazine | 1 | 2015 | 9 | 0.030 |
Why?
| | Genetic Markers | 1 | 2016 | 340 | 0.030 |
Why?
| | Observer Variation | 1 | 2016 | 356 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2016 | 176 | 0.030 |
Why?
| | Mutation | 1 | 2007 | 4093 | 0.030 |
Why?
| | Folic Acid | 1 | 2017 | 197 | 0.030 |
Why?
| | Texas | 1 | 2016 | 280 | 0.030 |
Why?
| | Animals | 2 | 2021 | 38107 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 447 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 997 | 0.030 |
Why?
| | Secondary Prevention | 1 | 2016 | 248 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2016 | 220 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2017 | 340 | 0.030 |
Why?
| | Abortion, Induced | 1 | 2016 | 112 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 790 | 0.030 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 299 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 2017 | 503 | 0.020 |
Why?
| | Acute Disease | 1 | 2016 | 1038 | 0.020 |
Why?
| | Postpartum Period | 1 | 2016 | 377 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1543 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1503 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 931 | 0.020 |
Why?
| | Mastectomy | 1 | 2014 | 189 | 0.020 |
Why?
| | Ultrasonography | 1 | 2016 | 788 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2018 | 1150 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 6073 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 164 | 0.020 |
Why?
| | Medical Oncology | 1 | 2014 | 345 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1665 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2921 | 0.020 |
Why?
| | Diet | 1 | 2017 | 1273 | 0.020 |
Why?
| | Kidney | 1 | 2017 | 1498 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 3200 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3416 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 1210 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1942 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2488 | 0.020 |
Why?
| | Electrophoresis | 1 | 2006 | 31 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 3647 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2007 | 410 | 0.010 |
Why?
| | Databases, Genetic | 1 | 2007 | 239 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2007 | 834 | 0.010 |
Why?
| | Collagen | 1 | 2007 | 460 | 0.010 |
Why?
| | Mice | 1 | 2021 | 18297 | 0.010 |
Why?
| | Binding Sites | 1 | 2007 | 1309 | 0.010 |
Why?
| | Protein Binding | 1 | 2007 | 2244 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2006 | 4118 | 0.010 |
Why?
|
|
Milgrom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|